Last reviewed · How we verify
Lorcaserin Dose #1 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lorcaserin Dose #1 (Lorcaserin Dose #1) — Eisai Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lorcaserin Dose #1 TARGET | Lorcaserin Dose #1 | Eisai Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lorcaserin Dose #1 CI watch — RSS
- Lorcaserin Dose #1 CI watch — Atom
- Lorcaserin Dose #1 CI watch — JSON
- Lorcaserin Dose #1 alone — RSS
Cite this brief
Drug Landscape (2026). Lorcaserin Dose #1 — Competitive Intelligence Brief. https://druglandscape.com/ci/lorcaserin-dose-1. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab